Clinical Trial Update: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Velcade (bortezomib) in combination with rituximab for relapsed or refractory indolent B-cell lymphoma has completed, including patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: B-Cell Lymphoma, Follicular Lymphoma | Phase 2 | Status: COMPLETED